Phibro Animal Health (NASDAQ:PAHC) Releases Quarterly Earnings Results, Beats Expectations By $0.14 EPS

Phibro Animal Health (NASDAQ:PAHC) released its quarterly earnings results on Wednesday. The company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.71 by $0.14, FiscalAI reports. Phibro Animal Health had a return on equity of 37.14% and a net margin of 6.35%.The business had revenue of $396.75 million during the quarter, compared to analysts’ expectations of $381.18 million. Phibro Animal Health updated its FY 2027 guidance to 3.410-3.590 EPS.

Phibro Animal Health Price Performance

Shares of NASDAQ PAHC traded up $0.16 during trading on Wednesday, hitting $36.09. 294,019 shares of the company were exchanged, compared to its average volume of 295,651. The company has a market cap of $1.46 billion, a price-to-earnings ratio of 15.49, a PEG ratio of 0.50 and a beta of 0.46. Phibro Animal Health has a 1 year low of $28.25 and a 1 year high of $60.08. The firm’s fifty day moving average price is $33.84 and its 200 day moving average price is $42.54. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.17 and a quick ratio of 1.26.

Phibro Animal Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Wednesday, September 2nd will be issued a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, September 2nd. This represents a $0.48 dividend on an annualized basis and a yield of 1.3%. Phibro Animal Health’s dividend payout ratio (DPR) is 20.60%.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on PAHC shares. Citigroup dropped their price objective on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a research note on Thursday, May 14th. Zacks Research cut shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 21st. Weiss Ratings downgraded shares of Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, June 15th. Finally, Wall Street Zen lowered shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $42.50.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State Street Corp lifted its position in shares of Phibro Animal Health by 5.4% during the 4th quarter. State Street Corp now owns 942,279 shares of the company’s stock valued at $35,204,000 after acquiring an additional 48,243 shares during the period. Millennium Management LLC boosted its stake in shares of Phibro Animal Health by 4,227.1% during the 4th quarter. Millennium Management LLC now owns 641,313 shares of the company’s stock worth $23,959,000 after acquiring an additional 626,492 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Phibro Animal Health by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 569,111 shares of the company’s stock worth $21,265,000 after acquiring an additional 21,951 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Phibro Animal Health by 1.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 492,335 shares of the company’s stock worth $18,394,000 after acquiring an additional 6,826 shares during the period. Finally, Invesco Ltd. increased its stake in Phibro Animal Health by 22.5% in the 3rd quarter. Invesco Ltd. now owns 322,299 shares of the company’s stock valued at $13,040,000 after purchasing an additional 59,226 shares in the last quarter. 99.34% of the stock is currently owned by institutional investors and hedge funds.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.